厄洛替尼治疗 CISH 阳性和 CISH 阴性 EGFR 基因改变的晚期肺腺癌患者。
Erlotinib treatment in patients with advanced lung adenocarcinoma with CISH-positive and CISH-negative EGFR gene alterations.
机构信息
Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital, 5 Fu-Shin Street, Kwei-Shan, Taoyuan 333, Taiwan, R.O.C.
出版信息
Anticancer Res. 2012 Mar;32(3):1107-12.
BACKGROUND
Epidermal growth factor receptor (EGFR) positivity as assessed by chromogenic in situ hybridization (CISH) has been demonstrated to be associated with EGFR mutation status. This study was conducted to compare the responsiveness of CISH-positive and CISH-negative lung adenocarcinomas to erlotinib.
PATIENTS AND METHODS
Patients received erlotinib (150 mg/day) alone until disease progression or intolerable toxicity. EGFR gene status was examined by CISH. The response rate (RR), progression-free survival (PFS), overall survival (OS) and toxicity profiles were assessed.
RESULTS
Thirty-one patients underwent response evaluations and CISH analyses, 12 of whom harboured CISH-positive adenocarcinomas. The overall RR (p=0.035), median PFS (p=0.091) and median OS (p=0.408) were higher in the CISH-positive group. No difference in toxicity profiles was observed between these two groups.
CONCLUSION
EGFR status as assessed by CISH can predict the response to erlotinib in patients with advanced lung adenocarcinoma.
背景
通过显色原位杂交（CISH）评估的表皮生长因子受体（EGFR）阳性与 EGFR 突变状态相关。本研究旨在比较 CISH 阳性和 CISH 阴性肺腺癌对厄洛替尼的反应。
患者和方法
患者接受厄洛替尼（150mg/天）单药治疗，直至疾病进展或不可耐受的毒性。通过 CISH 检测 EGFR 基因状态。评估反应率（RR）、无进展生存期（PFS）、总生存期（OS）和毒性谱。
结果
31 例患者进行了反应评估和 CISH 分析，其中 12 例为 CISH 阳性腺癌。CISH 阳性组的总体 RR（p=0.035）、中位 PFS（p=0.091）和中位 OS（p=0.408）较高。这两组之间的毒性谱没有差异。
结论
CISH 评估的 EGFR 状态可预测晚期肺腺癌患者对厄洛替尼的反应。
Zotero 插件